New atypical antipsychotics for schizophrenia: Iloperidone

Drug Design, Development and Therapy

Volumn , Issue 4, 2010, Pages 33-48

  Caccia, Silvio ^a   Pasina, Luca ^a   Nobili, Alessandro ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Efficacy; Iloperidone; Pharmacokinetics; Pharmacology; Safety

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CERAMINE KINASE LIKE PROTEIN; CLOZAPINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DEXTROMETHORPHAN; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DRUG METABOLITE; FLUOXETINE; GENE PRODUCT; HALOPERIDOL; HISTAMINE H1 RECEPTOR; ILOPERIDONE; KETOCONAZOLE; MUSCARINIC RECEPTOR; P 888991; PAROXETINE; PLACEBO; RISPERIDONE; SEROTONIN 2A ANTAGONIST; UNCLASSIFIED DRUG; ZIPRASIDONE; ISOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PIPERIDINE DERIVATIVE;

AGITATION; AKATHISIA; AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; BLOOD PRESSURE; BRIEF PSYCHIATRIC RATING SCALE; CHOLESTEROL BLOOD LEVEL; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEMETHYLATION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG OXIDATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; FOOD; FOOD DRUG INTERACTION; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MEAL; METABOLIC DISORDER; METABOLISM; NEGATIVE SYNDROME; NONHUMAN; ORTHOSTATIC HYPERTENSION; ORTHOSTATIC HYPOTENSION; PHARMACOGENETICS; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PROLACTIN BLOOD LEVEL; PSYCHOSIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RECEPTOR AFFINITY; RELAPSE; RESTLESSNESS; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SHORT COURSE THERAPY; SIDE EFFECT; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SOMNOLENCE; TACHYCARDIA; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WORKING MEMORY; XEROSTOMIA; GENETICS;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; ISOXAZOLES; PIPERIDINES; SCHIZOPHRENIA;

EID: 77953668586     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/dddt.s6443     Document Type: Review

References (61)

1. Saha S, Chant D, Welham J, Mgrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2(5):e141.
2. Stahl SM. Symptoms and circuits, part 3: schizophrenia. J Clin Psychiatry. 2004;65:8-9.
3. Seeman MV. Symptoms of schizophrenia: normal adaptations to inability. Med Hypotheses. 2007;69:253-257.
4. Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005;66:1122-1129.
5. HJ, McCabe R, Bullenkamp J, et al. Cost of treatment of schizophrenia in six European countries. Schizophr Res. 2009;1 11(1-3):70-77.
6. Rössler W, Salize HJ, van Os J, Riecher-Rössler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol. 2005;15(4):399-409.
7. Bondy B, Spellmann I. Pharmacogenetics of antipsychotics: useful for the clinician? Curr Opin Psychiatry. 2007;20(2):126-130.
8. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
9. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 1976;261(5562):717-719.
10. M, Lappin JM, Murray RM. Risk factors for schizophrenia-all roads lead to dopamine. Eur Neuropsychopharmacol. 2007; 17 Suppl 2: S101-S107.
11. RA. Partial response to antipsychotic treatment: the patient with enduring symptoms. J Clin Psychiatry. 1999;60 Suppl 23:10-13.
12. Luft B, Taylor D. A review of atypical antipsychotic drugs versus conventional medication in schizophrenia. Expert Opin Pharmacother. 2006;7(13):1739-1748.
13. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord. 2006;21(5): 589-598.
14. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features andmanagement. Drugs. 2004;64(20): 2291-2314.
15. HY. The role of serotonin in antipsychotic drug action. Neu-ropsychopharmacology. 1999;21(2):106S-115S.
16. Luft B, Taylor D. A review of atypical antipsychotic drugs versus conventional medication in schizophrenia. Expert Opin Pharmacother. 2006;7(13):1739-1748.
17. Bishara D, Taylor D. Upcoming agents for the treatment of schizo-phrenia: mechanism of action, efficacy and tolerability. Drugs. 2008;68(16):2269-2292.
18. Potkin SG. New advances in the treatment of schizophrenia. Introduction. J Clin Psychopharmacol. 2008;28(2 Suppl 1): S1-S3.
19. Citrome L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic. Int J Clin Pract. 2009;63(8):1237-1248.
20. JT, Bordeau KJ, Chang Y, et al. 3-[[(Aryloxy)alkyl]pi peridinyl]-1,2-benzisoxazoles as D2/5-HT2 antagonists with potential atypical antipsychotic activity: antipsychotic profile of iloperidone (HP 873). J Med Chem. 1985;28(6):761-769.
21. Caccia S. Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin Pharmacokinet. 2000;38(5): 393-414.
22. Kongsamut S, Roehr JE, Cai J, et al. Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur J Pharmacol. 1996;317: 417-423.
23. Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: A broad spectrum dopamine/serotonin/ norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology. 2001;25:904-914.
24. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors: Focus on newer generation compounds. Life Sci. 2000;68:29-39.
25. Kalkman HO, Feuerbach D, Lotscher E, Schoeffter P. Functional characterization of the novel antipsychotic iloperidone at human D2, D3, alpha2C, 5-HT6, and 5-HT1A receptors. Life Sci. 2003;73: 1151-1159.
26. Parsons B, Allison DB, Loebel A, et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res. 2009;110(1-3):103-110.
27. Szewczak MR, Corbett R, Rush DK, et al. The pharmacological profile of iloperidone, a novel atypical antipsychotic agent. J Pharmacol Exp Ther. 1995;274(3):1404-1413.
28. Barr AM, Powell SB, Markou A, Geyer MA. Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats. Neuropharmacology. 2006;51(3):457-465.
29. Corbett R, Hartman H, Kerman LL, et al. Effects of atypical antipsy-chotic agents on social behavior in rodents. Pharmacol Biochem Behav. 1993;45(1):9-17.
30. Hesselink JM. Iloperidone (Hoechst Marion Roussel Inc). IDrugs. 1999;2(6):584-590.
31. Nnadi CU, Malhotra AK. Clinical and pharmacogenetic studies of iloperidone. Personalized Medicine. 2008;5(4):367-375.
32. Gemperle AY, McAllister KH, Olpe HR. Differential effects of ilo-peridone, clozapine, and haloperidol on working memory of rats in the delayed non-matching-to-position paradigm. Psychopharmacology (Berl). 2003;169(3-4):354-364.
33. Fanapt (iloperidone tablets). Drug information http://www.rxlist.com/fanapt-drug.htm (accessed September 2009).
34. US Food and Drug Administration. Iloperidone, Approval Hystory, NDA 022192, review: (accessed September 2009).
35. SM, Hubbard JW, Chi E, et al. Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic. J Clin Pharmacol. 1995 Jul;35(7):713-720. Erratum in: J Clin Pharmacol. 1996;36(1):92.
36. Jain KK. An assessment of iloperidone for the treatment of schizophrenia. Expert Opin Investig Drugs. 2000;9(12):2935-2943.
37. Wang JS, Ruan Y, Taylor RM, et al. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J Neuropsychopharmacol. 2004;7(4):415-419.
38. Albers LJ, Musenga A, Raggi MA. Iloperidone: a new benzisoxazole atyp-ical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market? Expert Opin Investig Drugs. 2008;17(1):61-75.
39. Vermeir M, Naessens I, Remmerie B, et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos. 2008;36(4):769-779.
40. Mutlib AE, Strupczewski JT, Chesson SM. Application of hyphenated LC/NMR and LC/MS techniques in rapid identification of in vitro and in vivo metabolites of iloperidone. Drug Metab Dispos. 1995;23(9): 951-964.
41. Mutlib AE, Klein JT. Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Exp Ther. 1998;286:1285-1293.
42. Subramanian N, Kalkman HO. Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(3):553-560.
43. DeVane CL, Nemeroff CB. An evaluation of risperidone drug interactions. J Clin Psychopharmacol. 2001;21(4):408-416.
44. Corbett R, Griffiths L, Shipley JE, et al. Iloperidone: preclinical profile and early clinical evaluation. CNS Drug Rev. 1997;3:120-147.
45. Borison RL, Huff FJ, Griffiths L. Efficacy of 4 mg/day and 8 mg iloperidone administered to schizophrenic patients for 42 days. Psychopharmacol Bull. 1996;32:416.
46. Mucke HA, Castaner J. Iloperidone. Drug Future. 2000;25:29-40.
47. Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperi-done in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol. 2008;28(2 Suppl1):S4-S11.
48. Weiden PJ, Cutler AJ, Polymeropoulos MH, et al. Safety profile of iloperidone: a pooled analysis of 6-week acutephase pivotal trials. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S12-S19
49. Cutler AJ, Kalali AH, Weiden PJ, et al. Four week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol. 2008; 28(2 Suppl 1):S20-S28.
50. Kane JM, Lauriello J, Laska E, et al. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizo-phrenia. J Clin Psychipharmacol. 2008;28(2 Suppl 1):S29-S35.
51. J, Wolfang CD, Feeney J, Polymeropulos MH. Efficacy of iloperidone is comparable to risperidone in analyses of a placebo-and risperidone-controlled clinical trial for schizophrenia. (poster no. NR1-033) 162nd Annual Meeting of the American Psychiatric Association 2009 May 16-21; San Francisco (CA) USA.
52. J, Wolfang CD, Polymeropulos MH. The comparative efficacy of iloperidone and haloperidol across four short-term controlled trials. (poster no. NR1-026) 162nd Annual Meeting of the American Psychi-atric Association 2009 May 16-21; San Francisco (CA) USA.
53. Lavedan C, Volpi S, Polymeropulos MH, Wolfang CD. Effect of ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trial. Pharmacogenomics. 2008; 9:289-301.
54. Lavedan C, Licamele L, Volpi S, et al. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol Psychiatry. 2009;14:804-819.
55. Volpi S, Potkin SG, Malhotra AK, et al. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J Clin Psychiatry. 2009;70(6):801-809.
56. Volpi S, Heaton C, Mack K, et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol Psychiatry. 2009;14(11): 1024-1031.
57. Spina E, de Leon J. Metabolic drug interactions with newer anti-psychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007;100(1):4-22.
58. CD, Polymeropoulos MH. Single-nucleotide polymorphisms in the CYP2D6 gene are correlated with iloperidone drug exposure levels, impacting the degree of QTc prolongation associated with iloperidone treatment [abstract]. Presented at: the 57th Annual Meeting of the American Society of Human Genetics; 2007, October 23-27; San Diego, CA. Abstract 1040/T.
59. Scott LJ. Iloperidone: in schizophrenia. CNS Drugs. 2009;23(10): 867-880.
60. Roden DM. Drug induced prolongation of the QT interval. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10): 1013-1022.
61. Letsas KP, Efremidis M, Kounas SP, et al. Clinical characteristics of patients with drug-induced QT interval prolongation and torsades de pointes: identification of risk factors. Clin Res Cardiol. 2009;98: 208-212.